One Biotech looking for money with their focus on cancer treating drugs in various stages of clinical trials. BD
Seattle-based Cell Therapeutics is sending out an SOS signal to investors. "We have an immediate need to raise additional capital in the next thirty days in order to meet our operation needs," the company said in SEC documents. Cell Therapeutics also said that it does not have enough money to get through the current quarter. The biotech, which has yet to file its quarterly statement through June 30, stated that it ended the first quarter with $15.3 million in cash and $47.9 million in liabilities.
0 comments :
Post a Comment
Click to see the code!
To insert emoticon you must added at least one space before the code.